WeMed Raises Tens of Million Yuan Series C Financing

According to Yiou.com, WeMed Medical Equipment Co.Ltd. (WeMed) has announced the successful completion of tens of million yuan Series C financing. This latest funding round is led by Lucion, with participation from existing investors including Wuxi financial investment, Dongpingheng Investment, and EFung Capital, Haoyue Capital as the financial adviser. This round of financing will mainly be used for the clinical promotion of intelligent digital angiography machine and surgical C-arm after the certification, and accelerate the development of interventional robots and other products.

WeMed is a national enterprise of China specializing in interventional diagnosis and treatment solutions, with years of experience in the R&D and industrialization of digital angiography systems. The mission of WeMed is "Science and technology innovation, for life escort!". Its vision is to create a professional brand in the field of interventional medicine. At the same time, through overseas mergers and acquisitions and other forms, WeMed is devoted to achieving the international strategic layout of product research and development, manufacturing and marketing.

WeMed has many core R&D specialists of well-known medical enterprises in China and overseas, and has reached strategic cooperation with well-known universities and third-class hospitals in China and overseas. Based on the fundamental needs of its customers, WeMed constantly carries out product research and development and upgrading to maintain product innovation.

The so-called interventional diagnosis and treatment means that under the guidance of digital subtraction angiography (DSA), the medical personnel introduces special catheter, guidewire and other precision instruments into the human body to diagnose and treat diseases in vivo. DSA technology is recognized as the "gold standard" of interventional diagnosis and treatment due to its ability to build a real-time and accurate image. DSA technology is also one of the most effective means to detect vascular diseases.

Lucion is an influential professional venture capital institute and the first listed venture capital company in China. The company mainly invests in advanced manufacturing, modern agriculture, marine economy and other advantageous fields in Shandong, China, and other emerging industries including information technology, energy conservation & environmental protection, new energy, new materials, biotechnology and high-end equipment manufacturing.

EFUNG Investment is one of China's earliest institutions investing in professional biomedical industries. It has won 'The Most Pioneering VC Institution', 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VC Institutions in Shenzhen'. Over a decade of years, EFUNG Investment has been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors.